February 2008
TRASYLOLNovember 2007
Bayer Agrees to Withdraw Heart Surgery Drug - Trasylol
FDA Requests Marketing Suspension of Trasylol
Subject: MedEffect/MedEffet - Trasylol
October 2007
FDA anticipates re-evaluation of the overall risks and benefits of Trasylol
June 2007
Evaluating the Safety of Trasylol/aprotinin in cardiac surgery
May 2007
Aprotinin Injection (marketed as Trasylol) Information
The Risk Associated with Aprotinin Cardiac Surgery - The use of aprotinin was associated with a doubling in the risk of renal failure requiring dialysis among patients undergoing complex coronary-artery. Similarly, use of aprotinin was associated with a 55 percent increase in the risk of heart attack or heart failure and a marked increase in the risk of stroke or encephalopathy (brain disease associated with dementia).
April 2007
Bayer Discontinues Trasylol Clinical Trial Program In Non-CABG Indications
February 2007
Study Raises Safety Concerns About Heart-Surgery Drug - Trasylol
January 2007
Trasylol Gets Black Box Warning
December 2006
Trasylol: Pitfalls in Drug Review Process
Harvard Medical Professor Says Drug Safety Extinct
November 2006
Makers of Trasylol Failed to Tell the Truth to the FDA
